Retatrutide — Research Peptide

Retatrutide in the UK: buying, legal status and what to check

Retatrutide (development code LY3437943) is an investigational medicine. It has no marketing authorisation from the MHRA, the EMA, the FDA or any other regulator, it is not available on prescription in the UK, and the only route to it as a treatment is enrolment in a registered clinical trial. Phase 3 trials followed the Phase 2 programme described below and have reported since late 2025, but no approval has been granted anywhere at the time of writing; Lilly plans to apply for US approval in the first quarter of 2027, and UK availability would require MHRA authorisation. An MHRA warning in October 2025 said that any retatrutide offered for sale in the UK outside authorised clinical trials is likely to be illegal and potentially dangerous, and Lilly describes it as legally available only to participants in its trials. Free Muscle does not sell retatrutide as a medicine, a weight-management product or a food supplement. It is supplied as a research compound for laboratory use to adults aged 18 or over, and nothing on this page is treatment advice.

A trustworthy listing names the exact compound and its code name, states the quantity per capsule and the capsule count, identifies the batch, and can supply a certificate of analysis for that specific batch rather than a generic PDF. It is sold by a named seller, ships in plain packaging with tracking, and does not publish dosing, titration or "cycle" instructions, because the material is not supplied for human use. For this listing, every Free Muscle batch is assayed by Janoshik Analytical, an independent laboratory, the certificate for the batch is sent on request by email, and UK delivery is free, tracked and in plain packaging.

Capsules compared with pens, vials and other forms

Every published retatrutide trial used a once-weekly subcutaneous injection given under clinical supervision with gradual dose escalation. No oral form of retatrutide has been studied in humans, so a capsule is not the trial route and cannot be assumed to reproduce any trial finding. Peptides of this size face two barriers when swallowed: they are broken down by stomach acid and digestive proteases, and whatever survives crosses the gut wall poorly. Drucker's 2020 review describes the permeation enhancers and enzyme inhibitors developed to get round this. Buckley and colleagues (2018) showed that one oral GLP-1 receptor agonist tablet depends on co-formulation with the absorption enhancer SNAC and is absorbed in the stomach close to the tablet surface. No comparable formulation work has been published for retatrutide. What a capsule offers a laboratory is a fixed, assayed quantity of dry material in a sealed container. It does not change the pharmacology of oral peptide absorption.

Retatrutide compared with SARMs and other research compounds

Retatrutide and SARMs are often listed by the same shops, but they have nothing in common pharmacologically. SARMs, such as those in the SARMs collection, are small, orally active molecules that bind the androgen receptor. Retatrutide is a peptide built on a GIP-derived backbone and engineered to activate three receptors at once: GIP, GLP-1 and glucagon. Its published human data come from injected Phase 2 and Phase 3 trials, together involving several thousand participants with obesity, type 2 diabetes or steatotic liver disease. Compared with single-target compounds in the Metabolic Support collection, such as 5-Amino-1MQ, the main difference is the depth of evidence: retatrutide has randomised, placebo-controlled trials in thousands of participants, while most research metabolic compounds have cell or rodent data only. Compared with licensed incretin medicines, the only comparison made here is regulatory: those hold marketing authorisations and are prescribed with monitoring, and retatrutide holds none. For the wider class, see the peptides collection.

What the published research reports

Coskun and colleagues (2022) described the design of LY3437943 and its early clinical data. In laboratory assays it showed more activity at the GIP receptor than at the GLP-1 and glucagon receptors, and a first-in-human dosing study reported a tolerability profile similar to other incretin-based agents. Jastreboff and colleagues (2023) then randomised 338 adults with obesity, or overweight with a weight-related condition, to once-weekly subcutaneous retatrutide at one of several dose levels or placebo for 48 weeks. Mean weight change at 48 weeks ranged from about 9 per cent in the lowest-dose group to about 24 per cent in the highest, against about 2 per cent on placebo. Gastrointestinal adverse events were the most common, were dose-related and mostly mild to moderate, and were partly reduced by a lower starting dose. Heart rate rose in a dose-dependent way, peaked at 24 weeks and then declined.

Rosenstock and colleagues (2023) ran a parallel 36-week trial in 281 adults with type 2 diabetes against placebo and dulaglutide: HbA1c fell more than on placebo in all but the lowest dose group, and mild to moderate gastrointestinal events affected 35 per cent on retatrutide against 13 per cent on placebo. In 98 obesity-trial participants with metabolic dysfunction-associated steatotic liver disease, liver fat fell by a relative 43 to 82 per cent at 24 weeks, against little change on placebo, tracking body weight and abdominal fat (Sanyal 2024).

Results of three Phase 3 trials were published in 2026, all using once-weekly injection. TRIUMPH-1 followed 2,339 adults with obesity and no diabetes for 80 weeks: body weight fell on average by 17.6 to 25.0 per cent across the retatrutide groups, against 3.9 per cent with placebo, and gastrointestinal effects were the commonest adverse events (Jastreboff 2026).

TRIUMPH-2, in 1,152 adults with obesity and type 2 diabetes, reported more frequent hypotension and dysaesthesia (abnormal skin sensation) than placebo, and treatment stopped for adverse events or death in up to 12 per cent of a retatrutide group against 5 per cent on placebo (Bellido 2026). TRANSCEND-T2D-1, in 537 adults with type 2 diabetes over 40 weeks, reported 2 to 5 per cent stopping for adverse events against none on placebo, and no severe hypoglycaemia (Bajaj 2026).

These studies share important limits. All used injection, clinical supervision and dose escalation, all were funded by the manufacturer, and the longest published follow-up is 80 weeks. None of them is a claim about the capsules listed here.

Reading the certificate of analysis for this product

A Janoshik certificate for a retatrutide batch has several fields worth checking. Identity: the laboratory confirms, typically by liquid chromatography with mass spectrometry (LC-MS), that the material has the mass expected for retatrutide, which guards against a different peptide being sold under the name. Purity: a percentage, usually by HPLC, showing how much of the peptide content is the intact molecule rather than truncated or degraded fragments. Quantity: where reported, the amount found per capsule, which should be compared with the label. Batch number and test date: these tie the certificate to a specific production batch. A certificate without a batch number or date is a marketing document, not a batch record. To request the certificate for the batch you hold, contact us by email through the contact page. Our guide to reading a certificate of analysis explains each field in more detail. See also how we test.

Detection, sport and testing

Retatrutide is not named individually on the WADA Prohibited List. However, section S0 of the List (non-approved substances) prohibits at all times any pharmacological substance that is not covered by another section and has no current approval by any government health authority for human therapeutic use, which explicitly includes drugs in clinical development. As an investigational medicine approved nowhere, retatrutide should be treated as falling within S0. The List is revised each January, so athletes should check the current edition rather than rely on this page. No peer-reviewed study we have found reports a detection window for retatrutide in urine or blood, so the window is not established.

Storage, stability and handling

Peptides degrade through hydrolysis, oxidation and deamidation, and all three are accelerated by heat, moisture and light. Keep the container tightly sealed in a cool, dry, dark place, and do not transfer capsules to another container. Avoid repeatedly moving an opened container in and out of a fridge, since condensation on each opening introduces moisture. Handle with clean, dry gloves, label any sub-sample with the batch number, and dispose of unused material as laboratory waste. Keep out of reach of children and pets. The certificate's test date is the reference point for the stated purity.

Glossary

• LY3437943: the manufacturer's development code for retatrutide.
• GIP: glucose-dependent insulinotropic polypeptide, an incretin hormone released by the upper gut after eating.
• GLP-1: glucagon-like peptide 1, an incretin hormone that slows gastric emptying and stimulates insulin release.
• Glucagon receptor: the target of the pancreatic hormone glucagon, which raises glucose output from the liver.
• Phase 2 and Phase 3: mid-stage trials that explore dose and early efficacy, followed by larger confirmatory trials needed for licensing.
• Subcutaneous: injected into the fat layer under the skin, the route used in all published retatrutide trials.
• MASLD: metabolic dysfunction-associated steatotic liver disease, the current name for fatty liver linked to metabolic risk factors.
• WADA S0: the Prohibited List section covering substances with no approval for human therapeutic use.

Related compounds and reading

• Retatrutide collection
• Metabolic Support collection
• Research peptides
• SLU-PP-332 and 5-Amino-1MQ: what the mouse data show
• Do oral peptides actually work?
• What is Janoshik Analytical?
• SARMs vs peptides
• Shipping and delivery

Retatrutide is an investigational medicine that has not been authorised by the MHRA, EMA, FDA or any other regulator. This product is supplied for laboratory research only, is not a medicine or a food supplement, is not for human consumption, and is sold only to adults aged 18 or over. Nothing on this page is medical, dosing or treatment advice.

References

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315.
2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID: 37385280.
3. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID: 38858523.
4. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PMID: 35985340.
5. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277-289. PMID: 31848464.
6. Buckley ST, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. PMID: 30429357.
7. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. Online ahead of print. PMID: 42814954.
8. Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. Online ahead of print. PMID: 42810372.
9. Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. PMID: 42250575.